Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-2064

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-2064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636292064)

Label of Rivastigmine Transdermal System 13.3 mg/24 hours patch by Bryant Ranch Prepack. The label includes dosage strength, instructions to wear one patch at a time replaced every 24 hours, storage conditions, and a barcode. It states Rx only and indicates one unit per package.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure of the active ingredient rivastigmine, shown as a 2D molecular diagram featuring its atomic bonds and functional groups.*

FDA Label Image

Figure 1 (Rivastigmine 02)

An illustration diagram showing a cross-sectional layered view of the Rivastigmine Transdermal System patch, labeled with four distinct layers. The diagram includes arrows pointing to dimples on both the left and right sides of the patch structure.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A line graph showing Rivastigmine concentration (ng/mL) over time (hours) for three different dose strengths: 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. Each dose is represented by distinct markers with error bars, illustrating pharmacokinetic profiles for the extended-release transdermal patches over a 24-hour period.*

FDA Label Image

Figure 3 (Rivastigmine 04)

A line graph showing least square means with SEM change from baseline ADAS-Cog rating over 24 weeks of treatment. Four groups are compared: 17.4 mg/24 hours, 9.5 mg/24 hours, Capsules 6 mg BID, and Placebo. The graph indicates clinical improvement with the higher doses and clinical decline with placebo over time.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A bar graph displaying percentages of patients across categories of ADCS-CGIC ratings: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. Data are shown for treatment groups: 17.4 mg/24 hours patch, 9.5 mg/24 hours patch, Capsules 6 mg BID, and Placebo.*

FDA Label Image

Figure 5 (Rivastigmine 06)

A line graph showing change from baseline in ADCS-IADL scores over 52 weeks of treatment with Rivastigmine Transdermal System. Two lines represent doses of 9.5 mg/24hr and 13.3 mg/24hr, with score values on the vertical axis indicating clinical improvement or decline. Data points include error bars, mapping treatment effects over time.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A line graph depicting the ADAS-Cog change from baseline over 48 weeks of treatment for Rivastigmine Transdermal System at two strengths, 13.3 mg/24hr and 9.5 mg/24hr. The X-axis shows weeks of treatment, and the Y-axis shows LS means and SEM with clinical improvement and decline indicated. The graph compares cognitive changes at these two dosages over time.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph comparing LS mean changes with standard errors over 24 weeks of treatment for Rivastigmine Transdermal System in two sizes: 15 cm² (solid line) and 5 cm² (dashed line). The y-axis shows LS mean change with STE ranging from -8 to 3. Statistically significant differences favoring clinical improvement are noted at 16 and 24 weeks for the 15 cm² patch.*

FDA Label Image

Figure 8 (Rivastigmine 09)

A line graph comparing least squares mean change plus or minus standard error over 24 weeks of treatment for Rivastigmine Transdermal System 15 cm² and 5 cm² patches. The x-axis shows weeks of treatment (0, 8, 16, 24), and the y-axis shows LS mean change with clinical improvement and decline labeled. Statistical data with confidence intervals and p-values are shown above points at weeks 8, 16, and 24, indicating significance at weeks 16 and 24.*

FDA Label Image

Figure A (Rivastigmine 10)

Illustration of the Rivastigmine Transdermal System packaging and parts. It shows a labeled pouch containing the system, a round patch with protective liners on both sides, and a detailed view of the patch featuring rivastigmine adhesive with medicine and an outside backing. The diagram highlights the patch's components and protective features.*

FDA Label Image

Figure B (Rivastigmine 11)

Illustration showing possible application sites for the Rivastigmine Transdermal System patch on the body, including the left or right upper arm (side view), left or right side of the chest (front view), left or right upper back, and left or right lower back (both back views). The patch placement areas are highlighted with shaded rectangles.*

FDA Label Image

Figure C (Rivastigmine 12)

Illustration showing a hand holding a package of Rivastigmine Transdermal System patch being placed on a person's skin. The package is labeled with the product name and instructions indicating it is for transdermal use only and prescription use only.*

FDA Label Image

Figure D (Rivastigmine 13)

Instructional diagram showing how to remove the protective liners from a Rivastigmine Transdermal System patch. The image illustrates fingers peeling back liners to expose the sticky surface of the patch for application to the skin.*

FDA Label Image

Figure E (Rivastigmine 14)

An instructional illustration showing a person applying a transdermal patch on the upper back area. One hand is holding the patch in place, while the other hand appears to be pressing the patch onto the skin to secure it.*

FDA Label Image

Figure F (Rivastigmine 15)

An instructional illustration showing the upper back and shoulder area of a person with a hand positioned to apply a patch to the skin. This type of diagram typically accompanies transdermal patch drug products like Rivastigmine Transdermal System to demonstrate proper patch placement on the body.*

FDA Label Image

Figure G (Rivastigmine 16)

An instructional illustration showing a person applying a transdermal patch to the upper chest area. The image demonstrates the hands placing the patch on the skin, with arrows indicating the patch placement location and motion.*

FDA Label Image

Figure H (Rivastigmine 17)

Illustration showing instructions for disposing of a Rivastigmine Transdermal System 13.3 mg/24h patch. It depicts folding the sticky sides of the patch together, sliding the folded patch into its original pouch, and placing the pouch in the trash to keep it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.